ATE259663T1 - Positronenemissions-tomographie mit benutzung von gallium-68 chelaten - Google Patents

Positronenemissions-tomographie mit benutzung von gallium-68 chelaten

Info

Publication number
ATE259663T1
ATE259663T1 AT99921656T AT99921656T ATE259663T1 AT E259663 T1 ATE259663 T1 AT E259663T1 AT 99921656 T AT99921656 T AT 99921656T AT 99921656 T AT99921656 T AT 99921656T AT E259663 T1 ATE259663 T1 AT E259663T1
Authority
AT
Austria
Prior art keywords
dtpa
lys
complex
target site
chelate
Prior art date
Application number
AT99921656T
Other languages
English (en)
Inventor
Gary L Griffiths
William J Mcbride
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Application granted granted Critical
Publication of ATE259663T1 publication Critical patent/ATE259663T1/de

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT99921656T 1998-05-07 1999-05-06 Positronenemissions-tomographie mit benutzung von gallium-68 chelaten ATE259663T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8454898P 1998-05-07 1998-05-07
PCT/US1999/009759 WO1999056792A1 (en) 1998-05-07 1999-05-06 Positron emission tomography using gallium-68 chelates

Publications (1)

Publication Number Publication Date
ATE259663T1 true ATE259663T1 (de) 2004-03-15

Family

ID=22185670

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99921656T ATE259663T1 (de) 1998-05-07 1999-05-06 Positronenemissions-tomographie mit benutzung von gallium-68 chelaten

Country Status (8)

Country Link
EP (1) EP1075287B1 (de)
JP (1) JP2002513776A (de)
AT (1) ATE259663T1 (de)
AU (1) AU740563B2 (de)
CA (1) CA2331348C (de)
DE (1) DE69914892T2 (de)
ES (1) ES2216510T3 (de)
WO (1) WO1999056792A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US7011816B2 (en) 2001-12-26 2006-03-14 Immunomedics, Inc. Labeling targeting agents with gallium-68 and gallium-67
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1260827A (en) * 1984-08-31 1989-09-26 Richard C. Siegel Antibody-metal ion complexes
FR2652004B1 (fr) * 1989-09-21 1994-10-28 Immunotech Partners Nouveaux derives hydrophiles, application au diagnostic et a la therapeutique, kits diagnostiques ou therapeutiques et reactifs immunologiques.
ZA938243B (en) * 1992-11-12 1995-05-04 Hybritech Inc Altered affinity polypeptides of metal chelate binding antibodies
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype

Also Published As

Publication number Publication date
AU3880699A (en) 1999-11-23
EP1075287B1 (de) 2004-02-18
AU740563B2 (en) 2001-11-08
DE69914892D1 (de) 2004-03-25
WO1999056792A1 (en) 1999-11-11
DE69914892T2 (de) 2004-12-30
EP1075287A1 (de) 2001-02-14
CA2331348A1 (en) 1999-11-11
JP2002513776A (ja) 2002-05-14
ES2216510T3 (es) 2004-10-16
CA2331348C (en) 2007-07-24

Similar Documents

Publication Publication Date Title
D'Huyvetter et al. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody
Chang et al. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies
Vugts et al. Synthesis of phosphine and antibody–azide probes for in vivo Staudinger ligation in a pretargeted imaging and therapy approach
Wilbur et al. Antibody fragments in tumor pretargeting. Evaluation of biotinylated Fab ‘colocalization with recombinant streptavidin and avidin
Verhoeven et al. Therapeutic applications of pretargeting
JPS635033A (ja) 化合物標的化組成物
Liu et al. 90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy
JP2014500307A5 (de)
RU2004122695A (ru) Мечение галлием-68 и галлием-67 средств для направленной доставки
Arano et al. Chemical design of radiolabeled antibody fragments for low renal radioactivity levels
Rondon et al. Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept
Slastnikova et al. Preparation, cytotoxicity, and in vivo antitumor efficacy of 111In-labeled modular nanotransporters
US20060188441A1 (en) Radiolabeled gallium complexes, methods for synthesis and use for PET imaging of EGFR expression in malignant tumors
PT920623E (pt) Terapia de captura neutronica do bono utilizando metodo de pre-direccionamento
Karacay et al. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen
Sharkey et al. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody
Rogers et al. Targeted radiotherapy with [90Y]‐SMT 487 in mice bearing human nonsmall cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector
DE69914892D1 (de) Positronenemissions-tomographie mit benutzung von gallium-68 chelaten
Sugiyama et al. Cupid and Psyche system for the diagnosis and treatment of advanced cancer
Meredith et al. Pretargeted radioimmunotherapy
Zalutsky et al. Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution
Arano Strategies to reduce renal radioactivity levels of antibody fragments
Vriesendorp et al. Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease
AU2003241024A1 (en) Methods and compositions for radioimmunotherapy of brain and cns tumors
Li et al. Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1075287

Country of ref document: EP

REN Ceased due to non-payment of the annual fee